STE vs ZBH stock comparison
STERIS vs. Zimmer Biomet · data as of November 13, 2026
STERIS (STE) has a market value of about $25.7B, Zimmer Biomet (ZBH) about $19.5B. Over their latest twelve months STERIS had revenue of $6.2B and Zimmer Biomet $8.6B.
On our five checks STERIS scores higher: 3.0 out of 5 (average) against 2.2 (weak).
By area, the stronger company is Zimmer Biomet on value; STERIS on future growth; STERIS on track record; STERIS on financial health.
Zimmer Biomet is cheaper on earnings (P/E 26.1 vs. 31.4), while STERIS grew revenue faster over five years (13.8% vs. 6.1% a year).
STERIS leads on 11 of the compared lines and Zimmer Biomet on 11.
Side by side
| STE | ZBH | |
|---|---|---|
| Size and price | ||
| Market cap | $25.7B | $19.5B |
| Share price | $264.32 | $103.21 |
| Score | ||
| Overall score (of 5) | 3.0 | 2.2 |
| Value | 0 | 1 |
| Future growth | 2 | 1 |
| Track record | 3 | 1 |
| Financial health | 5 | 3 |
| Shareholder returns | 5 | 5 |
| Valuation | ||
| P/E (TTM) | 31.4 | 26.1 |
| Forward P/E | 21.7 | 11.4 |
| Price / free cash flow | 27.4 | 11.9 |
| Price / sales | 4.2 | 2.3 |
| EV / EBITDA | 16.2 | 11.7 |
| PEG | 2.76 | — |
| DCF value vs. price | −43% | −12% |
| Business | ||
| Revenue | $6.2B | $8.6B |
| Net income | $827M | $767M |
| Free cash flow | $937M | $1.6B |
| Net margin | 13.4% | 9.0% |
| Gross margin (5-yr avg.) | 43.9% | 71.0% |
| ROIC (5-yr avg.) | 6.8% | 4.8% |
| Growth | ||
| Revenue growth (1 yr) | 8.7% | 7.2% |
| Revenue growth (5 yrs, per year) | 13.8% | 6.1% |
| EPS growth (5 yrs, per year) | 11.4% | — |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$1.4B | -$7.1B |
| Dividend yield | 1.04% | 0.93% |
| Shareholder yield | 2.0% | 3.4% |
| Analysts | ||
| Upside to average target | +6% | +13% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: STE TTM to September 30, 2026, ZBH TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, STERIS or Zimmer Biomet?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) STERIS scores 3.0 out of 5 and Zimmer Biomet 2.2; the table shows where each one is stronger.
Is STERIS cheaper than Zimmer Biomet?
On trailing earnings, Zimmer Biomet trades at a P/E of 26.1 and STERIS at 31.4, so Zimmer Biomet is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, STERIS or Zimmer Biomet?
Over five years STERIS grew revenue about 13.8% a year and Zimmer Biomet about 6.1% a year.
Which pays a higher dividend?
STERIS yields 1.04% and Zimmer Biomet 0.93%.
Full STERIS analysis → Full Zimmer Biomet analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.